Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
- DOI
- 10.1007/s00280-013-2149-2
- Published
- 2013-03-30
- Container
- Cancer Chemother Pharmacol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00280-013-2149-2,
title = {Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.},
author = {Patnaik A and Papadopoulos KP and Tolcher AW and Beeram M and Urien S and Schaaf LJ and Tahiri S and Bekaii-Saab T and Lokiec FM and Rezaï K and Buchbinder A.},
year = {2013},
journal = {Cancer Chemother Pharmacol},
doi = {10.1007/s00280-013-2149-2},
url = {https://doi.org/10.1007/s00280-013-2149-2}
}RIS
TY - JOUR TI - Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. AU - Patnaik A AU - Papadopoulos KP AU - Tolcher AW AU - Beeram M AU - Urien S AU - Schaaf LJ AU - Tahiri S AU - Bekaii-Saab T AU - Lokiec FM AU - Rezaï K AU - Buchbinder A. PY - 2013 JO - Cancer Chemother Pharmacol DO - 10.1007/s00280-013-2149-2 UR - https://doi.org/10.1007/s00280-013-2149-2 ER -
APA
A, P., KP, P., AW, T., M, B., S, U., LJ, S., S, T., T, B., FM, L., K, R., & A., B. (2013). Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-013-2149-2
Source records
- europe-pmc · retrieved 2026-09-26T21:18:58.476Z